Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya
In addition to mosquito protection and vector control, two vaccines with a good efficacy profile based on the surrogate marker of seroprotection are now available to prevent chikungunya. While both vaccines showed acceptable tolerability, the safety of vaccines must be continuously assessed based on further data from post-marketing surveillance of the respective populations.
Authors
- Thomas G. P. Grünewald (ORCID: https://orcid.org/0000-0003-0920-7377)
- Kerstin Kling (ORCID: https://orcid.org/0000-0003-0223-0814)
- Camilla Rothe
- Annika Falman (ORCID: https://orcid.org/0009-0002-7176-0894)
- Lisa Branke
- Christian Schönfeld
- Michael Ramharter
Institutions
- Universität Hamburg (DE)
- Heidelberg University (DE)
- Robert Koch Institute (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Klinikum Chemnitz (DE)
- Ludwig-Maximilians-Universität München (DE)
- Bernhard Nocht Institute for Tropical Medicine (DE)
Publication Details
- Journal
- Vaccine
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128251
- Primary Topic
- Mosquito-borne diseases and control
- Type
- article
- Field-Weighted Citation Impact
- 0.00